VIRACEPT TABLETS 250MG

USDailyMed:Nelfinavir J05AE04(WHO) US:℞-only (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylphenyl)formamido]-4-(phenylsulfanyl)butyl]-decahydroisoquinoline-3-carboxamide 159989-64-7Y 64143 DB00220Y 57718Y HO3OGH5D7I D08259Y CHEBI:7496N ChEMBL1159655N 028590 DTXSID5035080 Interactive image O=C(c1cccc(O)c1C)N[C@@H](CSc2ccccc2)[C@H](O)CN4[C@H](C(=O)NC(C)(C)C)C[C@@H]3CCCC[C@@H]3C4 InChI=1S/C3​‍​​​​​‍​‍‍‍‍​‍‍2H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1YKey:QAGYKUNXZHXKMR-HKWSIXNMSA-NY Nelfinavir, sold under the brand nameViracept, is anantiretroviral medicationused in the treatment ofHIV/AIDS. Nelfinavir belongs to the class of drugs known asprotease inhibitors(PIs) and, like other PIs, it is almost always used in combination with other antiretroviral drugs. Nelfinavir is an orally bioavailable human immunodeficiency virusHIV-1 proteaseinhibitor (Ki= 2 nM) and is widely prescribed in combination withHIVreverse transcriptase inhibitors for the treatment of HIV infection. It was patented in 1992 and approved for medical use in 1997.